Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: Role of glycogen synthase kinase-3β inhibition

Critical Care Medicine

Volumn 34, Issue 5, 2006, Pages 1489-1496

  Dugo, Laura ^a   Collin, Marika ^a   Allen, David A ^a   Murch, Oliver ^a   Foster, Simon J ^b   Yaqoob, Muhammad M ^a   Thiemermann, Christoph ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Glucose; Glycogen synthase kinase 3 ; Inflammation; Insulin; Sepsis; TDZD 8

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PEPTIDOGLYCAN; SERINE; 4 BENZYL 2 METHYL 1,2,4 THIADIAZOLIDINE 3,5 DIONE; 4-BENZYL-2-METHYL-1,2,4-THIADIAZOLIDINE-3,5-DIONE; ANTIDIABETIC AGENT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INTERLEUKIN 1; THIADIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; INSULIN METABOLISM; INSULIN TREATMENT; MOLECULAR MECHANICS; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS; SHOCK; SURVIVAL RATE; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; BLOOD PRESSURE; CELL CULTURE; COMPARATIVE STUDY; DRUG ANTAGONISM; EVALUATION; HEART RATE; INFLAMMATION; MALE; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CELLS, CULTURED; GLYCOGEN SYNTHASE KINASE 3; HEART RATE; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MALE; PEPTIDOGLYCAN; PROSPECTIVE STUDIES; RANDOM ALLOCATION; RATS; RATS, WISTAR; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THIADIAZOLES; TRANSCRIPTION FACTOR RELA;

EID: 33646556651     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000215457.83953.E3     Document Type: Article

References (47)

1. Mesotten D, van den BG: Mechanisms of insulin-induced alterations in metabolism during critical illness. Nestle Nutr Workshop Ser Clin Perform Programme 2004; 69-75
2. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367
3. Cariou A, Vinsonneau C, Dhainaut JF: Adjunctive therapies in sepsis: An evidence-based review. Crit Care Med 2004; 32:S562-S570
4. van den Berghe G, Wouters PJ, Bouillon R, et al: Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 2003; 31:359-366
5. van den Berghe G: Role of intravenous insulin therapy in critically ill patients. Endocr Pract 2004; 10 (Suppl 2):17-20
6. Cross DA, Alessi DR, Cohen P, et al: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-789
7. Shaw M, Cohen P, Alessi DR: Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett 1997; 416:307-311
8. Frame S, Cohen P: GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359:1-16
9. Van Wauwe J, Haefner B: Glycogen synthase kinase-3 as drug target: From wallflower to center of attention. Drug News Perspect 2003; 16:557-565
10. Woodgett JR: Judging a protein by more than its name: GSK-3. Sci STKE 2001; 2001:RE12
11. Embi N, Rylatt DB, Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle: Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107:519-527
12. Cohen P, Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2:769-776
13. Dugo L, Collin M, Allen DA, et al: GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 2005; 33:1903-1912
14. Thiemermann C, Ruetten H, Wu CC, et al: The multiple organ dysfunction syndrome caused by endotoxin in the rat: Attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol 1995; 116:2845-2851
15. Baue A: The multiple organ or system failure syndrome. In: Pathophysiology of Shock, Sepsis and Organ Failure. Shlag G, Redl H (Eds). Berlin, Springer Verlag, 1993, pp 1004-1018
16. Hewett JA, Jean PA, Kunkel SL, et al: Relationship between tumor necrosis factor-alpha and neutrophils in endotoxin-induced liver injury. Am J Physiol 1993; 265:G1011-G1015
17. Martinez A, Alonso M, Castro A, et al: First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002; 45:1292-1299
18. Jeschke MG, Klein D, Bolder U, et al: Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 2004; 145:4084-4093
19. Maitra SR, Chen E, Rosa D, et al: Modulations of signal transduction pathways during sepsis and the effects of insulin and mifepristone. Acad Emerg Med 2003; 10:1-8
20. Foster SJ: Analysis of the autolysins of Bacillus subtilis 168 during vegetative growth and differentiation by using renaturing polyacryl amide gel electrophoresis. J Bacteriol 1992; 174:464-470
21. Kirschning CJ, Wesche H, Merrill AT, et al: Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 1998; 188:2091-2097
22. Dugo L, Collin M, Cuzzocrea S, et al: 15d-prostaglandin J(2) reduces multiple organ failure caused by wall-fragment of Gram-positive and Gram-negative bacteria. Eur J Pharmacol 2004; 498:295-301
23. Wray GM, Foster SJ, Hinds CJ, et al: A cell wall component from pathogenic and non-pathogenic Gram-positive bacteria (peptidoglycan) synergises with endotoxin to cause the release of tumour necrosis factor-alpha, nitric oxide production, shock, and multiple organ injury/dysfunction in the rat. Shock 2001; 15:135-142
24. Das UN: Current advances in sepsis and septic shock with particular emphasis on the role of insulin. Med Sci Monit 2003; 9:RA181-RA192
25. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150
26. Lewis KS, Kane-Gill SL, Bobek MB, et al: Intensive insulin therapy for critically ill patients. Ann Pharmacother 2004; 38:1243-1251
27. Preiser JC, Devos P, Van den BG: Tight control of glycaemia in critically ill patients. Curr Opin Clin Nutr Metab Care 2002; 5:533-537
28. van der Horst I, Zijlstra F, van't Hof AW, et al: Glucose-insulin- potassium infusion in patients treated with primary angioplasty for acute myocardial infarction: The glucose-insulin-potassium study: A randomized trial. J Am Coll Cardiol 2003; 42:784-791
29. Kagansky N, Levy S, Rimon E, et al: Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med 2003; 163:1825-1829
30. Cohen P, Goedert M: GSK3 inhibitors: Development and therapeutic potential. Nat Rev Drug Discov 2004; 3:479-487
31. Steinbrecher KA, Wilson W, III, Cogswell PC, et al: Glycogen synthase kinase 3β functions to specify gene-specific, NF-κB-dependent transcription. Mol Cell Biol 2005; 25:8444-8455
32. Martin M, Rehani K, Jope RS, et al: Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005; 6:777-784
33. Demarchi F, Bertoli C, Sandy P, et al: Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem 2003; 278:39583-39590
34. Hoeflich KP, Luo J, Rubie EA, et al: Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406:86-90
35. Schwabe RF, Brenner DA: Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 2002; 283:G204-G211
36. Takada Y, Fang X, Jamaluddin MS, et al: Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 2004; 279:39541-39554
37. Aljada A, Ghanim H, Saadeh R, et al: Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001; 86:450-453
38. Aljada A, Ghanim H, Mohanty P, et al: Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 2002; 87:1419-1422
39. Dandona P, Aljada A, Mohanty P, et al: Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: Evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001; 86:3257-3265
40. Eldar-Finkelman H: Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol Med 2002; 8:126-132
41. Wang X, Li W, Lu J, et al: Lipopolysaccharide suppresses albumin expression by activating NF-kappaB in rat hepatocytes. J Surg Res 2004; 122:274-279
42. Brix-Christensen V, Andersen SK, Andersen R, et al: Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: An experimental study in a porcine model. Anesthesiology 2004; 100:861-870
43. Jeschke MG, Einspanier R, Klein D, et al: Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Med 2002; 8:443-450
44. Klein D, Schubert T, Horch RE, et al: Insulin treatment improves hepatic morphology and function through modulation of hepatic signals after severe trauma. Ann Surg 2004; 240:340-349
45. Hansen TK, Thiel S, Wouters PJ, et al: Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counter-acts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003; 88:1082-1088
46. Siroen MP, van Leeuwen PA, Nijveldt RJ, et al: Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: A possible explanation of reduced morbidity and mortality? Crit Care Med 2005; 33:504-510
47. Martin M, Rehani K, Jope RS, et al: Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005; 6:777-784